Advancing Lentiviral Vector Manufacturing: A Platform For Commercial Cell Therapy Success

By Bojiao Yin, Process Development, ElevateBio Basecamp

The presentation highlights BaseCamp’s LentiPeak™ platform, a scalable and robust lentiviral vector (LVV) manufacturing process specifically engineered to support ex vivo cell therapy applications. Designed with commercial-readiness in mind, LentiPeak™ delivers high-yield, high-quality vector production across clinical and pre-commercial scales.

Key findings presented include:

• Strong performance under GMP conditions, demonstrating consistent product quality and batch-to-batch reproducibility;
• Validation of a scale-down model that accurately reflects large-scale performance, enabling predictive process development and efficient tech transfer; and
• Clinical-scale capacity assessments, with data showing the ability to meet vector demands for both early- and late-phase clinical programs from a single manufacturing batch.

Beyond process optimization, BaseCamp is implementing a holistic strategy that integrates rigorous process design, real-world clinical feedback, and a risk-based development framework. This approach provides a well-defined and efficient pathway from clinical development to full commercial deployment of LV-based therapies, aligning regulatory compliance with long-term manufacturing sustainability.